Meta-analysis
Apart from two recent studies conducted in 201926 and
202013, all the studies included in the meta-analysis
had already been evaluated and reported in the meta-analysis of Mallah
et al., 2019.29 The latter found there was no
heterogeneity among the studies included in their meta-analysis. In our
study, we observed heterogeneity in the macrolide meta-analysis, but not
for the macrolide subclasses. Results of the pooled estimates, including
the findings for the current study, did not show a significant increased
risk of CHD following first trimester use of macrolides, erythromycin,
clarithromycin or azithromycin (Figure 3 A - D).